Erica DiNapoli


Team Up, Be Aggressive: Improving Outcomes for Metastatic Colon Cancer

January 14, 2021

The management of patients with colorectal liver metastases is complicated and requires careful assessment from a multidisciplinary tumor board—especially in light of recent advances made with chemotherapy, according to Michael J. Cavnar, MD.

More Targets Discovered, More Molecular Testing Needed in Lung Cancer

January 09, 2021

Molecular testing is a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET, according to Yujie Zhao, MD, PhD, who added that the integration of RNA-based sequencing into these strategies could potentially provide further benefit to patients.

Personalized Approach May Boost AI Adherence

January 06, 2021

Twice-weekly text message reminders did not improve adherence to aromatase inhibitors (AIs) for postmenopausal patients with early-stage breast cancer; therefore, increasing the odds of long-term adherence for this population will require more personalized approaches, explained Julie Gralow, MD.

HER2-Positive Breast Cancer Biomarkers: The Search Continues

January 05, 2021

Patients with early-stage HER2-positive breast cancer should be treated with neoadjuvant therapy rather than surgery to determine how they will respond to ado-trastuzumab emtansine (T-DM1; Kadcyla)in the adjuvant setting, according to Ian E. Krop, MD, PhD, who added that although residual disease may serve as a potential predictive biomarker for response to this approach, the hunt for effective molecular biomarkers continues.

Chemoimmunotherapy Combos Push Forward in TNBC Treatment

December 27, 2020

Several novel chemoimmunotherapy combinations have risen to the forefront of treatment in triple-negative breast cancer (TNBC), according to Neelima Vidula, MD. However, what the optimal chemotherapy backbone is, which PD-L1 assay should be utilized, and whether this approach will play a role in the neoadjuvant setting are all questions that remain unanswered.

Precision Medicine Highlights the Importance of Biomarkers in Melanoma

December 04, 2020

With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.

CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning

November 29, 2020

Following the approvals of tisagenlecleucel (tisa-cel; Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta), several research efforts have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas, according to Olalekan O. Oluwole, MBBS, MD, who added that although this modality has moved the needle forward, this approach is not without toxicity.

Personalized Treatment Is Paramount in Colorectal Cancer

November 17, 2020

Colorectal cancer (CRC) treatment has entered an era that is both exciting and challenging, according to Nilofer S. Azad, MD, who emphasized that as new strategies continue to be explored, treatment decisions should be informed by tumor location, the alterations present, and tolerability.

Better Disease Biology Is Needed to Improve Melanoma Outcomes

November 05, 2020

Despite the recent advancements with BRAF-targeted therapies and PD-1 checkpoint inhibitors, there is still much to learn in the field of melanoma, especially with regard to disease biology, according to Jason J. Luke, MD, FACP, who added that this understanding is needed to inform development and sequencing strategies, as emphasized during the 2020 SMR Virtual Congress.

Expert Talks Pembrolizumab for TMB-High Tumors

October 24, 2020

The FDA approval of pembrolizumab (Keytruda) for use in select adult and pediatric patients with unresectable or metastatic solid tumors that are tumor mutational burden (TMB)-high, has both generated a lot of excitement and been hotly debated, according to Vivek Subbiah, MD.